After encountering specific antigen, naive CD4 + T cells become activated, expand their populations and differentiate into various effector T cell subsets, such as T helper type 1 (T H 1), T H 2 or interleukin 17 (IL-17)-producing T helper (T H -17), characterized by distinct patterns of cytokine secretion. These subsets of T cells have specific effector functions and recruit different cell types at the site of inflammation by virtue of the cytokines they produce. T-bet, GATA-3 and RORgt are the transcription factors required for the generation of T H 1, T H 2 and T H -17 cells, respectively [1] [2] [3] . Whereas T H 1 cells clear intracellular pathogens and mediate autoimmune tissue inflammation, T H 2 cells are required for the clearance of extracellular pathogens, and an exaggerated T H 2 response induces asthma, allergy and atopy. In contrast, T H -17 cells seem to be involved in controlling both intracellular and extracellular pathogens and in orchestrating autoimmune tissue inflammation 4, 5 . As exaggerated responses by T H 1, T H 2 and T H -17 cells can induce tissue inflammation, the maintenance of immune homeostasis and prevention of immunopathology requires tight regulatory mechanisms to control these effector T cells by subsets of regulatory T cells (T reg cells). Various types of T cells have been described that mediate these regulatory functions in vivo and prevent autoimmunity and tissue inflammation. The CD4 + CD25 + Foxp3 + and IL-10-producing T reg type 1 (Tr1) cells are crucial in regulating effector T cell functions 6, 7 . Naturally occurring T reg cells, which are generated in the thymus and express the transcription factor Foxp3 (A002750), inhibit effector T cells and are crucial in the maintenance of peripheral tolerance 8 . In addition, emerging data suggest that Foxp3 + T cells can also be generated in the peripheral immune compartment [9] [10] [11] . However, the in vivo factors that generate inducible Foxp3 + T reg cells in the periphery are still unclear.
In vitro, transforming growth factor-b (TGF-b; A002271), together with the T cell antigen receptor and costimulatory signals, can induce Foxp3 and generate T reg cells from naive T cells 12 . TGF-b seems to be a crucial factor in this process, as mice deficient in TGF-b1 have a defect in the maintenance Foxp3 + T reg cells and develop a lethal lymphoproliferative disorder characterized by enhanced T H 1 and T H 2 effector responses. In addition, Foxp3 + T cells from mutant 'FILIG' mice, which have attenuated expression of Foxp3, produce more T H 2 cytokines 13 ; this indicates that Foxp3 negatively regulates the T H 2 developmental program. How Foxp3 regulates T H 2 responses, whether it is cell intrinsic (in which Foxp3 suppresses induction of T H 2-specific transcription factors) or whether T reg cells suppress T H 2 cells indirectly has not been tested directly. Initial reports suggest that Foxp3 can bind to the T H 2 lineage-specific transcription factor GATA- 3 (refs. 14,15) , but the consequences of this interaction are not well understood. One outcome of this interaction, however, is that Foxp3 can directly inhibit the development of T H 2 cells.
In addition to Foxp3 + T reg cells, Tr1 cells can suppress effector T cell function and tissue inflammation independently of Foxp3 expression. Tr1 cells produce mainly IL-10 (A001243) and suppress immune responses in a contact-independent way through the production of IL-10. Although IL-10 was initially shown to induce Tr1 differentiation, the Tr1 cells thus generated do not proliferate because of the suppressive nature of IL-10. That observation suggests that factors other than IL-10 might be important for the differentiation and population expansion of IL-10-secreting Tr1 cells. Several papers have demonstrated that IL-27 together with TGF-b induces the differentiation of Tr1 cells 16, 17 . The IL-10-producing Tr1 cells thus generated have potent immunosuppressive properties in that they not only inhibit autoimmune disease and tissue inflammation but also contribute to the successful engraftment of HLA-mismatched bone marrow transplants 6 . However, IL-10-producing T cells are not always anti-inflammatory, and in some circumstances they have been shown to promote autoimmunity 18, 19 . It has not yet been elucidated whether these IL-10-producing cells also produce other cytokines that negate the antiinflammatory function of IL-10, nor have the differences between these pro-and anti-inflammatory IL-10-producing cells been determined.
In this study we show that IL-4, a T H 2-differentiating cytokine, inhibited TGF-b-induced Foxp3 expression and thus suppressed the new generation of Foxp3 + T reg cells. Unexpectedly, the two cytokines together (TGF-b plus IL-4) induced the generation of mainly Foxp3 -IL-9 + IL-10 + T cells that, unlike Tr1 cells, did not suppress T cell responses even though they produced IL-10. More unexpectedly, the IL-9 + IL-10 + T cells not only induced the development of colitis but also induced peripheral neuritis when transferred together with CD45RB hi CD4 + effector T cells into mice deficient in recombinationactivating gene 1 (RAG-1). IL-9 was initially cloned as a T cell growth factor whose receptor shares the common g-chain with IL-2, IL-4, IL-7, IL-15 and IL-21 20 , and it has shown to be involved in T H 2-type immunity against helminth infection 21 . Our data suggest that T cells differentiating in the presence of IL-4 and TGF-b undergo a unique developmental program characterized by the production of IL-10 and IL-9, which may not only subvert the immunosuppressive function of IL-10-producing cells but also promote tissue inflammation, probably by regulating the population expansion and/or function of other effector T cells. 12, 16 . To test the effect of IL-4 on the induction of Foxp3 by TGF-b, we used green fluorescent protein-negative (GFP -) naive CD4 + T cells from mice with a bicistronic enhanced GFP reporter cloned into the endogenous Foxp3 locus (Foxp3-GFP mice) 12 . As expected, stimulation of the T cell antigen receptor in the presence of TGF-b induced Foxp3-GFP expression in up to 80% of T cells, and this was inhibited (to 22%) in the presence of IL-4 (Fig. 1a) ; thus, IL-4 actively inhibits the induction of Foxp3 in the presence of TGF-b. To understand the mechanism by which IL-4 mediates the inhibition of Foxp3 expression, we assessed the cytokines produced by T cells activated in the presence of TGF-b plus IL-4. Naive CD4 + T cells stimulated in the presence of IL-4 differentiated into T H 2 cells and produced IL-10, IL-5, IL-13 and very little IL-9. The combination of TGF-b plus IL-4 inhibited the production of IL-4, IL-13 and IL-5 while sparing IL-10 production by these T cells. Furthermore, activation in the presence of TGF-b plus IL-4 also induced the secretion of large amounts of IL-9 (Fig. 1b,c and Supplementary Fig. 1 online) . Notably, T cell populations expanded in the presence of TGF-b plus IL-4 produced as much IL-10 as T H 2-differentiated T cells did, but instead of IL-4 but they produced IL-9 together with IL-10 ( Fig. 1b and Supplementary Fig. 2a online) . To determine whether antigen-presenting cells (APCs) contributed to the generation of this unique subset of IL-9 + IL-10 + cells or whether IL-9 was being produced by APCs, we also activated naive CD4 + T cells with plate-bound antibody to CD3 (anti-CD3) and anti-CD28 (without any APCs) in the presence of TGF-b together with IL-4. Even in the absence of APCs, IL-4 inhibited the generation of TGF-b-induced Foxp3 + T cells and induced T cells that co-produced IL-9 and IL-10 ( Supplementary Fig. 2a) .
RESULTS

IL-4 inhibits
To characterize the source of IL-10 production at the cellular level, we did intracellular cytokine staining and compared T cells activated in the presence of TGF-b, IL-4 or both. Activation of naive T cells in the presence of IL-4 did not induce Foxp3-GFP expression but did induce the production of intracellular IL-4 and IL-10, as expected, as a part of T H 2 development. We found no production of either interferon-g (IFN-g) or IL-17 by responding T cells. However, the addition of IL-4 to TGF-b inhibited Foxp3 expression and induced mainly production of IL-10 from these cells with much less production of T H 2 cytokines, including IL-4 ( Fig. 1c) . We could not stain for IL-9 at the single-cell level because of the lack of appropriate antibody reagents. Therefore, we could not establish the coexpression of IL-10 and IL-9 at the cellular level in the T cells differentiated by TGF-b plus IL-4. However, these T cells produced both IL-9 and IL-10, as assessed by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (Fig. 1b and Supplementary Fig. 1b-d) .
To determine whether IL-9 production was dependent on IL-10 in T cells differentiated with TGF-b plus IL-4, we obtained naive T cells from mice with a GFP reporter cloned into the Il10 locus (IL-10-GFP reporter mice) 22 and differentiated the cells in the presence of TGF-b plus IL-4. Then we sorted IL-10-GFP + and IL-10-GFP -T cells by flow cytometry on the basis of GFP expression. We detected IL-9 mRNA expression in IL-10-GFP + and IL-10-GFP -cells ( Supplementary  Fig. 2a ), although we found maximum expression only when IL-10-GFP + and IL-10-GFP -cells were together. These T cells differentiated with TGF-b plus IL-4 produced both IL-9 and IL-10 and we did not detect any double-producing IL-10 + IL-17 + or IL-10 + IFN-g + cells ( Supplementary Fig. 2b ). Supplementary Fig. 2b ). These results show that like IL-6 and IL-27, IL-4 is also able to inhibit Foxp3 induction and induce production of mainly IL-9 and IL-10 from the responding T cells.
Studies have shown that IL-10-producing Tr1 cells do not proliferate well and seem to acquire an anergic phenotype. However, IL-9 + IL-10 + T cells induced in the presence of TGF-b plus IL-4 were not anergic and vigorously proliferated when activated by anti-CD3 (Fig. 1d) . We did not detect expression of T-bet, GATA-3, Foxp3 or RORgt (lineage-specific transcription factors necessary for the generation of T H 1, T H 2, T reg and T H -17 cells, respectively) in the T cells differentiated with TGF-b plus IL-4 (Fig. 1e) . TGF-b may act together with other cytokines to induce new T cell subsets 23 (Fig. 1e) .
IL-4 inhibition of Foxp3 induction depends on STAT6
To understand the function of IL-4 in the active inhibition of TGF-binduced Foxp3, we cultured naive T cells from IL-4-transgenic mice in the presence of various concentrations of TGF-b. Unexpectedly, TGF-b, even at higher doses, did not induce the generation of Foxp3 + T reg cells (Fig. 2a) , which suggested that IL-4 may be dominant in inhibiting the induction of Foxp3 expression. After binding to its receptor, IL-4 induces several signaling pathways, including those of insulin receptor substrate 2 and STAT6 (Signal Transducer and Activator of Transcription 6), which form a signaling complex in association with the cytoplasmic tail of the IL-4 receptor 24 . However, STAT6 is the dominant pathway of T H 2 differentiation because it induces GATA-3, the 'master' transcription factor for T H 2 differentiation. To assess whether STAT6 was involved in inducing IL-4-mediated Foxp3 inhibition, we crossed STAT6-deficient (STAT6-knockout (STAT6-KO)) mice with the Foxp3-GFP 'knock-in' mice to generate a 'STAT6-KO.Foxp3-GFP' strain.
We purified naive CD4 + T cells from Foxp3-GFP and STAT6-KO.Foxp3-GFP mice and cultured the cells in the presence of TGF-b or IL-4 or a combination of these two cytokines. Unlike Foxp3-GFP T cells, in which IL-4 inhibited the induction of Foxp3, STAT6-KO.Foxp3-GFP T cells had higher expression of Foxp3 (80%) even in the presence of TGF-b plus IL-4 (Fig. 2b) . Furthermore, when we analyzed the cytokines produced by the STAT6-deficient cells Cytokine (ng/ml) RORγt expression (relative stimulated in the presence of TGF-b plus IL-4, we found that IL-10 and IL-9 were not induced, but these cells continued to express Foxp3 in the presence of TGF-b plus IL-4 ( Fig. 2c,d ). As GATA-3 is 'downstream' of STAT6, we also analyzed the induction of IL-9 and IL-10 by TGF-b plus IL-4 in GATA-3-deficient T cells and found that, similarly to the STAT6-deficient cells, GATA-3-deficient T cells could not produce IL-9 or IL-10 upon differentiation in the presence of TGFb plus IL-4 (Fig. 2e) . The effect of STAT6 and GATA-3 on the induction of IL-9 + IL-10 + T cells may be indirect rather than direct, as in the absence of STAT6-GATA-3 signaling, TGF-b-induced Foxp3 could not be antagonized by IL-4, resulting in the induction of mainly Foxp3, which may not allow the differentiation of T cells to produce IL-9 and IL-10. These data collectively suggest that the inhibition of Foxp3 expression by IL-4 is mediated through the IL-4-STAT6 pathway. Thus, the new generation of inducible Foxp3 + T reg cells is probably modulated by the IL-4 through the activation of the STAT6-GATA-3 pathway. We next explored whether the IL-4-STAT6 pathway affected the function of already established, naturally occurring Foxp3 + T reg cells. When we cultured sorted Foxp3 -T effector cells with either Foxp3-GFP + or STAT6-KO.Foxp3-GFP + T reg cells, Foxp3-GFP + T reg cells lost much of their suppressive ability in the presence of IL-4, whereas STAT6-KO.Foxp3-GFP + T reg cells still remained partly suppressive despite the presence of IL-4 (40% versus 70% suppression; Fig. 2f) . Thus, the IL-4-STAT6 pathway not only affects the generation of induced T reg cells but also regulates the suppressive capacity of naturally occurring T reg cells by a mechanism intrinsic to T reg cells.
Relationship between and Foxp3 and GATA-3
To assess whether GATA-3 affects Foxp3 expression, we isolated CD4 + T cells from GATA-3 conditional knockout mice and activated the cells in the presence of TGF-b. On day 4 after activation, we collected T cells and extracted mRNA for analysis of the expression of GATA-3 and Foxp3 by quantitative PCR. TGF-b-induced Foxp3 mRNA expression was threefold higher in GATA-3-deficient CD4 + T cells than in wildtype CD4 + T cells. However, the addition of TGF-b resulted in less GATA-3 expression in wild-type CD4 + T cells (Fig. 3a) , which suggested possible inter-regulation between these two transcription factors.
Because of the correlation between the expression of Foxp3 and GATA-3, we sought to determine whether the two transcription factors could physically interact and associate with each other. We used two different approaches to test those possibilities. In the first approach, we transfected human embryonic kidney cells (HEK293 cells) with Flag-tagged GATA-3 and Renilla luciferase-tagged control protein) with anti-Flag and assessed Foxp3 in the immunoprecipitates by monitoring the expression of Renilla luciferase by luminescence. Precipitation of GATA-3 resulted in much more luciferase activity than did negative control (empty vector) or another transcription factor, such as STAT6 (Fig. 3b) , which suggested that GATA-3 precipitated luciferase-tagged Foxp3. We further confirmed those results in the second approach, using a coimmunoprecipitation assay. For this, we transfected cells with Flag-tagged GATA-3 together with Myc-tagged Foxp3. After lysing the cells, we immunoprecipitated the lysates with beads coated with anti-FLAG. To detect whether Foxp3 precipitated together with GATA-3, we separated the samples by SDS-PAGE and, after transfer, blotted the membrane with antiMyc. GATA-3 immunoprecipitated together with Foxp3 (data not shown), which demonstrated direct association of the two proteins. These assays show that GATA-3 and Foxp3 physically associate with each other.
Functional interaction between Foxp3 and GATA-3 Next we sought to determine the functional importance of the interaction reported above by assessing whether Foxp3 affected T H 2 differentiation. We cloned Foxp3 into a retroviral vector (mouse stem cell virus) and transduced this vector into activated CD4 + T cells differentiated in T H 2-polarization conditions (10 ng/ml IL-4 and 10 mg/ml anti-IL-12). We then sorted T cells expressing Foxp3 by flow cytometry, extracted RNA and analyzed the expression of various cytokines. In parallel, we maintained a cohort of cells from each transduction condition in culture for 2-3 d, restimulated them with plate-bound anti-CD3 and anti-CD28 and collected the supernatants for cytokine analysis by ELISA.
Whereas T cells transduced with empty retroviral vector had high expression of Il10, Il13 and Il4 mRNAs and modest expression of Il5, consistent with T cells differentiated into T H 2 effector cells, T cells transduced with Foxp3 had much less expression of Il4, Il15 and Il13 but retained substantial expression of Il10. Similarly, at the protein level, T cells transduced with control vector produced IL-4 and small amounts of IL-2, whereas Foxp3-transduced T cells produced less IL-4 and more IL-10 (Fig. 3c) . This was consistent with our initial observation that activation of T cells in the presence of IL-4 plus TGF-b resulted in the inhibition of production of IL-4, IL-5, IL-13 but spared IL-10 production by these cells. This would suggest that Foxp3 interferes with the expression of genes controlled by GATA-3, presumably by binding or interfering with its ability to transactivate specific T H 2 genes. In particular, these results suggest that the interaction of Foxp3 with GATA-3 inhibits its ability to transactivate promoters that are under the control of GATA-3, such as those of genes encoding IL-4, IL-5 and IL-13 but not IL-10, which is most likely controlled by a different transcription factor.
To address our hypothesis, we analyzed the ability of Foxp3 to inhibit GATA-3-mediated transactivation of an Il5 promoter-luciferase construct. We transfected Jurkat cells with GATA-3, Foxp3 or both GATA-3 and Foxp3 in the presence of the Il5 promoter-luciferase construct and measured luciferase activity after activating the cells with the phorbol ester PMA plus ionomycin. As expected, GATA-3 strongly transactivated activity of the Il5 promoter-luciferase construct, whereas this effect was 50% lower when Foxp3 was coexpressed (Fig. 3d) . These results collectively show that Foxp3 can directly interact with GATA-3 and that this association inhibits GATA-3-mediated transactivation of Il5, which is one of its target genes.
Function of IL-9 + IL-10 + Foxp3 -T cells As IL-10-producing Tr1 cells have been shown to suppress T cell proliferation in vitro and to inhibit tissue inflammation in vivo 25 , we wanted to determine whether naive T cells differentiated in the presence of TGF-b plus IL-4 that produced IL-9 and IL-10 were also suppressive. Although Foxp3 + T reg cells were anergic and inhibited the proliferation of effector T cells in vitro, T cells generated in the presence of TGF-b plus IL-4 were not anergic or suppressive, as they vigorously proliferated on their own and, together with effector T cells, further enhanced T cell proliferation (Fig. 4a) . The addition of neutralizing antibodies to IL-9 or IL-10 to the cultures of effector T cells with IL-10-GFP + T cells generated by TGF-b plus IL-4 resulted in less proliferation but did not completely abolish it (Fig. 4a) . These data suggest that unlike Foxp3 + T reg cells and IL-10-producing Tr1 cells, T cells induced by TGF-b plus IL-4 do not have any suppressive effects in vitro but readily proliferate and thus act like effector T cells.
It is apparent not only that Tr1 cells suppress proliferation in vitro but also that IL-10-producing cells can suppress the induction of colitis in vivo 26, 27 . Therefore, to further characterize the IL-9 + IL-10 + T cells generated in the presence of both TGF-b and IL-4, we assessed their function in vivo in a T cell transfer model of colitis. We purified naive T cells from IL-10-GFP reporter mice and activated the cells in the presence of TGF-b and IL-4. At day 4, we used flow cytometry to sort the IL-10-GFP + T cells treated with TGF-b plus IL-4 (T4-IL-10-GFP + T cells) on the basis of GFP expression. We reconstituted RAG-1-deficient mice with effector T cells (Foxp3 -CD45RB hi T cells), with effector T cells plus T4-IL-10-GFP + T cells, with only T4-IL-10-GFP + T cells, or with effector T cells plus naturally occurring T reg cells, and then assessed the development of colitis by monitoring the body weight of the mice and assigning scores for colitis as described before 28 . We also did histopathological analysis to evaluate the induction and severity of the disease. All mice reconstituted with effector T cells did not lose much weight but developed severe colitis, as noted by histopathology, with an average colitis score of 7.5 ± 3.5 (Fig. 4b) . As a control to show that effector T cells can indeed be regulated, we demonstrated that mice that received both effector T cells and naturally occurring T reg cells were protected from both clinical and histological disease (average colitis score, 3.7 ± 1.5). Notably, mice that received T cells cultured in the presence of TGFb plus IL-4 lost weight and developed a more moderate colitis (average colitis score, 5.7 ± 2.6). Furthermore, when we transferred effector T cells together with IL-9 + IL-10-GFP + T cells generated in the presence of TGF-b and IL-4, the mice lost the most weight and histopathology showed the development of a more severe colitis than that of mice given effector T cells alone (average colitis score, 8.8 ± 2.3; Fig. 4c) . Unexpectedly, however, mice receiving either solely T4-IL-10-GFP + T cells or both effector T cells (CD45RB hi ) and T4-IL-10-GFP + T cells also showed signs of clinical neurological disease characterized by impaired motor coordination with flaccid monoparesis or asymmetric paraparesis of the hind limbs. Muscle strength and tone in forelimbs and tail did not seem to be affected. These clinical signs differed from the typical manifestations of experimental autoimmune encephalitis (characterized by a limp tail and ascending paralysis) and suggested instead a peripheral neuropathy. Consistent with the clinical appearance, histopathological analysis showed evidence of peripheral neuritis in mice that received both effector T cells and T4-IL-10-GFP + T cells or only T4-IL-10-GFP + T cells. However, consistent with the clinical results, we found no inflammation in the brain or spinal cord (Fig. 4c) . At weeks 8-9 after transfer and after the development of colitis, we killed mice and retrieved cells from lymph nodes to assess cytokine production by intracellular cytokine staining. T cells from the RAG-1-deficient mice that received only effector (CD45RB hi ) T cells produced mostly IFN-g and very little IL-17 ( Supplementary Fig. 3a online) . However, T cells from the mice receiving both effector (CD45RB hi ) T cells and T4-IL-10-GFP + T cells produced both IL-17 and IFN-g, but the production of IL-17 predominated over that of IFN-g in these cells. And although we noted expression of both IL-17 and IFN-g in IL-10-GFP + and IL-10-GFP -cells, over a third of the IL-10-GFP + cells also produced both IL-17 and IFN-g ( Supplementary Fig. 3b ). These data suggest that T cells generated in the presence of TGF-b and IL-4 that produce both IL-9 and IL-10 do not act as T reg cells but instead potentiate the functions of effector T cells, which results in additional tissue inflammation not induced by the transfer of effector T cells alone.
DISCUSSION
Here we have shown that when naive T cells were activated in the presence of both IL-4 and TGF-b, Foxp3 expression was inhibited and a subset of T cells was generated that selectively produced IL-10 and IL-9. Although IL-10-producing cells are known to have regulatory properties, the IL-9-IL-10-producing cells described here did not regulate but instead induced tissue inflammation. IL-4 is involved in T H 2 differentiation, and the observation that IL-4 receptor signals are transduced by the transcription factors STAT6 and GATA-3 is well © 2008 Nature Publishing Group http://www.nature.com/natureimmunology described. So far, no lineage-specific transcription factors have been identified for IL-10-producing Tr1 cells. It has been suggested that GATA-3 may participate in the transcriptional regulation of IL-10. However, our data have demonstrated that IL-9-IL-10-producing cells induced in presence of TGF-b and IL-4 did not express GATA-3, which suggests that the presence of TGF-b could antagonize the induction of GATA-3, yet these cells continued to produce IL-10.
STAT proteins are important in T cell differentiation 29 . STAT6 is involved in T H 2 differentiation, and a STAT1-binding site has been found in the Il10 promoter 29, 30 . In this study, we have shown that the inhibition of TGF-b-induced Foxp3 + T cells by IL-4 and the generation of T cells IL-9 + IL-10 + was partially reversed in STAT6-deficient and GATA-3-deficient mice, which suggests that STAT6 and GATA-3 may be important in the generation of cells producing both IL-9 and IL-10. However, an alternative interpretation of our data is that in the absence of IL-4 signaling in STAT6-deficient and GATA-3-deficient mice, there is mainly unopposed induction of Foxp3, which prevents the differentiation of T cells to produce IL-9 and IL-10. The lack of GATA-3 expression in IL-9-IL-10-producing cells induced by TGF-b plus IL-4 would partly support that interpretation.
In addition to IL-10, IL-9 was produced by T cells differentiated in the presence of TGF-b plus IL-4, which suggests that TGF-b was not simply 'scaling back' T H 2 responses but instead that TGF-b and IL-4 together were inducing a new gene program that induced IL-9 production. We did not address whether the combined effects of TGF-b and IL-4 induced another transcription factor not associated with either with T H 2 or T reg cells. Notably, Foxp3 and GATA-3 physically associated with each other; this finding is perhaps reminiscent of the interaction between Foxp3 and RORgt, which reciprocally regulates the induction of T reg or T H -17 cells 12, 31 . Binding of Foxp3 to GATA-3 may regulate the molecular mechanism by which TGF-b and IL-4 mutually inhibit the generation of T reg and T H 2 cells. However, this mutual regulation resulted in the production of IL-9 by the differentiating T cells. During the course of our studies, two other groups reported that Foxp3 and GATA-3 physically associate with each other 14, 15 . Our results have confirmed those findings and have shown that Foxp3 not only interacted with GATA-3 but also inhibited the ability of GATA-3 to transactivate the promoter of a T H 2 target gene, Il5.
TGF-b together with IL-27 can induce and expand populations of IL-10-producing cells that also produce IFN-g and have strong immunoregulatory properties 16 . IL-10 is a potent anti-inflammatory cytokine that inhibits T H 1-, T H -17-and T H 2-mediated immune responses [32] [33] [34] . The importance of IL-10 in regulating immune responses has been demonstrated in human infectious diseases such as tuberculosis, malaria, leishmaniasis and schistosomiasis [35] [36] [37] . In addition to being produced by T cells, IL-10 can be produced by many other cell types, including macrophages, dendritic cells, B cells and natural killer cells. IL-10 production by T cells is important in the downregulation of T cell population expansion during antigen-specific immune responses. Although Tr1 cells produce considerable IL-10, they can also produce variable amounts of IFN-g and are able to suppress in vitro T cell responses in a Foxp3-independent way. Such findings have led to the view that IL-10 produced by T cells is important in suppressing inflammation. Here we have shown that IL-10-producing cells could be generated in large numbers when naive T cells were cultured in the presence of IL-4 plus TGF-b; however, these T cells also produced IL-9, lacked regulatory properties and failed to control inflammation when transferred in vivo. The production of IL-10 and TGF-b is associated with the maintenance of peripheral tolerance by T reg cells 25 . In vivo, the absence of IL-10 exacerbates airway inflammation 38 . Such data indicate that the production of IL-10 by T cells may not always have suppressive functions and that the context in which IL-10 is produced by T cells may be equally important in determining whether IL-10-producing T cells are anti-inflammatory or proinflammatory.
It is known that IL-10 is important in regulating tissue inflammation in the gut. More specifically, it has been shown that IL-10 produced by T reg cells is essential for this in vivo suppression, as IL-10-deficient T reg cells cannot 'cure' T cell transfer-induced colitis 27, 39 . In our study, the IL-10-producing T cells generated in the presence of TGF-b and IL-4 induced colitis and, when transferred together with effector T cells, not only failed to prevent the development of disease but also induced peripheral neuritis, a disease not induced by effector T cells (CD4 + CD45RB hi ) alone. These data suggest that the IL-9 + IL-10 + Foxp3 -T cells generated in the presence of TGF-b and IL-4 did not have suppressive functions and therefore represent a unique population of IL-10-producing T cells that promote inflammation. It is not clear at this stage whether IL-9 or IL-10 or both cytokines is (are) involved in inducing tissue inflammation, but we believe that IL-9 produced by these T cells may be a key factor in promoting their proinflammatory activity. This is consistent with the observation that IL-9 in the lung promotes T H 2-mediated allergic pulmonary disease characterized by abundant T H 2 cytokines 40, 41 . We also have found that IL-9 receptors are expressed on effector T cells (data not shown) and that these cells therefore have the potential to respond to IL-9 and differentiate in the presence of IL-9 + IL-10 + cells. As IL-9 belongs to the cytokine family of IL-2, IL-4, IL-7, IL-15 and IL-21 and uses the common g-chain to function, we believe that IL-9 produced by T cells stimulated with TGF-b and IL-4 may function as a growth and differentiation factor for other effector T cells. This, we believe, is one of the explanations why IL-9 + IL-10 + Foxp3 -T cells were not able to control inflammatory responses but instead acted in synergy with effector cells to potentiate their proinflammatory activity. Consistent with that view were the data obtained with RAG-1-deficient recipients of a mixture of effector T cells and IL-9 + IL-10 + T cells, which showed that the effector T cells produced IL-17 not normally found when effector cells alone were transferred into RAG-1-deficient mice.
In addition to expression of the IL-9 receptor on effector T cells, our preliminary data have indicated that the IL-9 receptor is also expressed on naturally occurring T reg cells. Therefore, IL-9 could exert its effects on both effector T cells and T reg cells. Whether IL-9 inhibits or interferes with the suppressive functions of regulatory cells has not been analyzed. However, IL-9 is also produced by T reg cells themselves 42 ; this IL-9 recruits mast cells to the tissue niche and regulates effector T cells during graft rejection. Neutralization of IL-9 in vivo in this setting abrogates T reg cell function and promotes graft rejection. In our experiments, we tested the effects of IL-9-IL-10-producing T cells in vivo in RAG-1-deficient mice in the absence of T reg cells; in these experimental conditions, the IL-9 produced by the IL-9-IL-10-producing T cells may have acted only on the effector T cells and potentiated their proinflammatory functions and thus induced more severe and unusual tissue inflammation (such as peripheral neuritis), not normally noted with the transfer of effector T cells alone.
In conclusion, here we have identified a previously unknown subset of T cells generated in presence of TGF-b and IL-4 that produced both IL-9 and IL-10, did not suppress T cell responses and promoted inflammation. Thus, depending on the context in which IL-10 is being produced by T cells, the T cells can inhibit inflammation and protect against autoimmunity, or they can promote inflammation and mediate tissue destruction.
METHODS
Mice. C57BL/6 mice, BALB/c mice, RAG-1-deficient (Rag -/-) mice and STAT6-deficient (Stat6 -/-) mice were from Jackson Laboratories. Foxp3-GFP mice 12 , IL-4-transgenic mice 43 and IL-10-GFP reporter mice 22 have been described. Mice with conditional GATA-3 deficiency (Gata3 flox/flox ) and IL-10-GFP mice were provided by I.-C. Ho and R. Flavell, respectively. Mice were housed in conventional, pathogen-free facilities at the Harvard Institute of Medicine. All experiments were done in accordance with guidelines of the standing committee on animals at Harvard Medical School.
In vitro T cell differentiation, proliferation and suppression assays. For T cell differentiation and proliferation, sorted naive CD4 + CD62L + Foxp3-GFP -, CD4 + CD62L + GATA-3-KO (Cre + ) or CD4 + CD62L + STAT6-KO.Foxp3-GFP -T cells were cultured with irradiated syngenic APCs in the presence of TGFb (3 ng/ml), IL-4 (20 ng/ml) or both. For suppression assays, 2.0 Â 10 4 sorted Foxp3 + T reg cells from wild-type or STAT6-deficient mice were cultured together in triplicate wells at a ratio of 1:1 with naive wild-type CD4 + T cell or naive STAT6-deficient CD4 + T cells (T cell responders) in the presence of soluble anti-CD3 (1 mg/ml; BioXCell, clone 145-2C11) and irradiated syngenic APCs. In some experiments, anti-IL-9 (10 mg/ml; BD Biosciences, clone D9302C12) or anti-IL-10 (10 mg/ml; BD Biosciences, clone JES-16E3) was added to the culture. Cells were pulsed with Intracellular cytokine staining. Cells previously stimulated with either soluble anti-CD3 together with irradiated APCs or with plate-bound anti-CD3 and anti-CD28 were restimulated for 4 h at 37 1C in 10% CO 2 with PMA (phorbol 12-myristate 13-acetate; 50 ng/ml; Sigma), ionomycin (1 mg/ml; Sigma) and GolgiStop (1 ml per 1.5 ml; BD Bioscience), followed by surface and intracellular staining of various cytokines according to the manufacturer's instructions (BD Bioscience). Cells were analyzed on a flow cytometer (BD Biosciences).
In vivo T cell transfer-induced colitis. C57BL/6 RAG-1-deficient mice were injected with sorted CD4 + Foxp3-GFP -CD45RB hi T cell subpopulations in PBS as described 44, 45 . Mice received CD4 + Foxp3-GFP -CD45RB hi T cells alone or in combination with CD4 + CD62L + T cells from IL-10-GFP mice stimulated with TGF-b and IL-4, or with naturally occurring CD4 + Foxp3 + T reg cells. Weight loss was monitored for 9 weeks. Mice were then killed and samples of colonic lymphoid tissues as well as brain and spinal cord were fixed in neutral buffered formalin.
Histopathology. Routinely processed, paraffin-embedded samples of small and large intestine and other tissues were stained with hematoxylin and eosin. Sections of brain and spinal cord were stained with Luxol fast blue plus hematoxylin and eosin. The presence and severity of colitis and the presence of brain and spinal cord inflammation was evaluated by researchers 'blinded' to sample identity.
The severity of colitis was graded semiquantitatively for the following four criteria on a scale of 0-3: degree of epithelial hyperplasia and goblet cell depletion; leukocyte infiltration in the lamina propria; area of tissue affected; and the presence of markers of severe inflammation, such as crypt abscesses, submucosal inflammation and ulcers. Scores for each criterion were added to give an overall inflammation score of 0-12 for each sample. The total colonic score was calculated as the average of the individual scores of sections of proximal colon, mid-colon and distal colon 28 .
Measurement of cytokines by ELISA and quantitative RT-PCR. Culture supernatants were collected at 48 h to assess cytokine production by ELISA or cytometric bead array (BD Bioscience). RNA was extracted with RNAeasy columns (Qiagen) after 48-96 h of in vitro stimulation and was analyzed by quantitative RT-PCR according to the manufacturer's instructions (Applied Biosystem).
Retroviral transduction of T cells with conditional deletion of GATA-3 and T H 2-polarized T cells. Total CD4 + T cells from wild-type mice or mice with loxP-flanked Gata3 were transduced with a mouse stem cell virus-based retroviral vector expressing Foxp3 or Cre recombinase, respectively. This retroviral vector is a bicistronic vector encoding enhanced GFP, whose expression 'reports' the expression of the transgene. The retroviral particles were produced by cotransfection of plasmids encoding group-associated antigenpolymerase and the ecotropic envelope plus the retroviral vector into the HEK293 cell line with FuGENE (Roche). Retroviral supernatants were collected 48-72 h after transfection and were centrifuged before use. Freshly isolated CD4 + T cells purified by magnetic-activated cell sorting were activated with plate-bound anti-CD3 (BioXCell, clone 145-2C11) and anti-CD28 (BioXCell, clone PV-1) in the presence of mouse IL-4 (10 ng/ml; R&D Systems) and antimouse IL-12 (10 mg/ml; BD Biosciences, clone C17.8) for T H 2 differentiation. After 24 h of activation, retroviral supernatant was added to the cells together with polybrene (8 mg/ml). Plates were centrifuged for 45 min at 720g and were then returned to 37 1C. TGF-b (3 ng/ml) was added to some samples to induce Foxp3 expression. After 48 h of incubation at 37 1C, GFP + cells were purified by flow cytometry and their populations were expanded for an additional 48-72 h in the presence of IL-2.
Luciferase assays. HEK293 cell lines were transiently cotransfected with Renilla luciferase-tagged Foxp3 and Flag-tagged GATA-3, Foxp1 or STAT6. FuGENE 6 was used for transfection according to the manufacturer's instructions (Roche). Cell extracts were prepared (Promega) and samples were immunoprecipitated with beads coated with anti-Flag (Sigma, clone M2). Renilla luciferase expression was assessed by detection of luminescence.
Jurkat cells were transfected with a BioRad electroporator (260 V); 5 Â 10 6 cells in 0.4 ml RPMI medium were transfected with 5 mg reporter plasmid (Il5 promoter-luciferase) and 20 mg expression plasmid. Luciferase assays were done after activation of the cells for 3 h with PMA and ionomycin.
Accession codes. UCSD-Nature Signaling Gateway (http://www.signaling-gate way.org): A002750, A002271 and A001243. 
